BioPorto Diagnostics


DKK664.4m market cap

DKK4.01 last close

BioPorto is a diagnostic company focused on the development and marketing antibodies and other products for research and diagnostics. This includes a portfolio of products marketed for research use and The NGAL Test, which the company has submitted to the FDA for the prediction of acute kidney injury.

Investment summary

BioPorto announced on 3 October 2018 that it had received feedback from the FDA on its outstanding 510(k) application for The NGAL Test for risk use with acute kidney injury (AKI). The agency said that additional data would be required to support a ‘rule-out’ claim (ie that the test can exclude the risk of AKI). The company is engaged in discussions with the agency and has revised its timeline: an FDA decision in mid-2019.

Y/E Dec
Revenue (DKKm)
EPS (ore)
P/E (x)
P/CF (x)
2016A 20.7 (22.6) (22.4) (157.0) N/A N/A
2017A 25.2 (33.1) (33.7) (203.0) N/A N/A
2018E 29.6 (37.6) (37.2) (209.0) N/A N/A
2019E 34.7 (17.7) (17.0) (91.0) N/A N/A
Last updated on 19/02/2019
Industry outlook

The current standard of care for detecting AKI is serum creatinine, which can take 24 hours or more to detect AKI and can only do so after significant kidney damage. NGAL promises to provide a quicker and more reliable test, allowing early intervention to preserve kidney function.

Last updated on 19/02/2019
Share price graph
Balance sheet
Forecast net cash (DKKm) 12.4
Forecast gearing ratio (%) N/A
Price performance
Actual 2.6 4.7 11.5
Relative* (2.0) (2.3) 13.9
52-week high/low DKK6.2/DKK3.0
*% relative to local index
Key management
Thomas Magnussen Chairman
Peter Mørch Eriksen CEO
Ole Larsen CFO
Jan Kuhlmann Andersen COO